Table 1 Relative proportion of secreted proteins determined by SDS-PAGE analysis (day 2)
| Â | E1AB1 | E1AB1-XA3 | ||||
|---|---|---|---|---|---|---|
– | ΔCBH1 Caplacizumab | ΔCBH1 ΔCBH2 Caplacizumab | – | ΔCBH1 Caplacizumab | ΔCBH1 ΔCBH2 Caplacizumab | |
AaBGL1 | 1.6 | 1.0 | 0.6 | 0.6 | 0.4 | 2.0 |
BXL1 | 4.5 | 3.6 | 4.9 | 2.0 | 4.5 | 5.7 |
CBH1 | 26.9 | 0.0 | 0.0 | 31.2 | 0.0 | 0.0 |
CBH2 + EGL1 | 26.6 | 24.0 | 2.5 | 29.0 | 34.4 | 9.8 |
EGL2 + EGL4 | 17.7 | 9.5 | 1.9 | 19.6 | 20.0 | 26.0 |
XYN3 | 4.3 | 7.8 | 9.8 | 2.1 | 2.0 | 3.1 |
Caplacizumab | 0.0 | 12.2 | 23.2 | 0.2 | 9.4 | 21.1 |
EGL3 | 6.3 | 10.9 | 17.2 | 3.2 | 3.2 | 5.6 |
XYN1 + XYN2 | 5.0 | 9.1 | 13.2 | 4.3 | 11.9 | 11.0 |
others | 7.1 | 21.8 | 26.7 | 7.9 | 14.2 | 15.6 |
Total | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |